30
300453.SHE Jiangxi Sanxin Medtec Co Ltd
- Market cap
- CNY 4.92B
- P/E
- 16.5x
- P/B
- 3.14x
- ROE
- 18.1%
- Dividend yield
- 3.32%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300453.SHE undervalued?
Graham number300453.SHE trades 51.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangxi Sanxin Medtec Co Ltd fundamental analysis
No fundamental analysis for Jiangxi Sanxin Medtec Co Ltd yet.
Jiangxi Sanxin Medtec Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangxi Sanxin Medtec Co Ltd
Jiangxi Sanxin Medtec Co.,Ltd. engages in the research and development, manufacture, sale, and service of medical devices. It offers infusion and cardiothoracic surgery products and blood purification products, such as central concentrate delivery systems, disposable biological protein glue dispensers, disposable blood dialyzers, hemodialysis filters, hemodialysis concentrates and powders, continuous blood purification pipelines and accessories, dialysis fluid filters, dispo…
Full company profileJiangxi Sanxin Medtec Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangxi Sanxin Medtec Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 318M | 404M | 531M | 722M | 940M | 1.16B | 1.34B | 1.30B | 1.50B | 1.64B | 1.74B |
| Gross Profit | 106M | 125M | 159M | 248M | 304M | 400M | 449M | 453M | 528M | 591M | 624M |
| Operating Income | 43.5M | 49.0M | 48.0M | 77.5M | 155M | 195M | 230M | 258M | 279M | 323M | 352M |
| EBITDA | 57.9M | 70.3M | 79.0M | 118M | 205M | 253M | 292M | 331M | 369M | 323M | 347M |
| Net Income | 36.6M | 42.4M | 41.1M | 61.7M | 116M | 156M | 185M | 207M | 227M | 262M | 280M |
| EPS | 0.07 | 0.09 | 0.08 | 0.12 | 0.22 | 0.30 | 0.36 | 0.40 | 0.44 | 0.51 | 0.54 |
| Balance Sheet | |||||||||||
| Total Assets | 625M | 671M | 827M | 1.15B | 1.24B | 1.41B | 1.79B | 2.03B | 2.22B | 2.43B | 3.04B |
| Total Liabilities | 72.6M | 88.7M | 217M | 428M | 400M | 427M | 631M | 697M | 814M | 875M | 1.42B |
| Shareholders' Equity | 553M | 579M | 606M | 669M | 785M | 906M | 1.08B | 1.25B | 1.32B | 1.46B | 1.55B |
| Cash & Short-term Investments | 71.7M | 87.5M | 82.4M | 131M | 207M | 251M | 361M | 363M | 468M | 431M | 558M |
| Total Debt | - | - | 82.4M | 133M | 113M | 42.1M | 129M | 202M | 198M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 61.3M | 62.3M | 58.9M | 167M | 273M | 330M | 402M | 346M | 390M | 461M | - |
| Capital Expenditure | 112M | 89.1M | 132M | 123M | 98.1M | 175M | 211M | 287M | 218M | 242M | 268M |
| Free Cash Flow | -50.4M | -26.9M | -73.5M | 44.3M | 175M | 155M | 192M | 52.3M | 172M | 219M | 110M |
| Ratios | |||||||||||
| ROE | 6.6% | 7.3% | 6.8% | 9.2% | 14.7% | 17.2% | 17.2% | 16.6% | 17.2% | 18.0% | 18.1% |
| ROA | 5.9% | 6.3% | 5.0% | 5.4% | 9.3% | 11.1% | 10.3% | 10.2% | 10.2% | 10.8% | 9.2% |
| Net Profit Margin | 11.5% | 10.5% | 7.7% | 8.5% | 12.3% | 13.4% | 13.8% | 15.9% | 15.2% | 16.0% | 16.1% |
| Debt to Equity | - | - | 0.14x | 0.20x | 0.14x | 0.05x | 0.12x | 0.16x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangxi Sanxin Medtec Co Ltd dividends
- Dividend yield
- 3.32%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 62.2%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 163M | 0.32 | 62.2% |
| 2024 | CNY 132M | 0.26 | 58.0% |
| 2023 | CNY 59.6M | 0.11 | 28.8% |
| 2022 | CNY 59.1M | 0.11 | 32.0% |
| 2021 | CNY 52.5M | 0.10 | 33.7% |
| 2020 | CNY 26.3M | 0.05 | 22.7% |
| 2019 | CNY 16.3M | 0.03 | 26.5% |
| 2018 | CNY 17.6M | 0.04 | 42.8% |
| 2017 | CNY 15.9M | 0.03 | 37.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.32:1 on Apr 24, 2023.
Who owns Jiangxi Sanxin Medtec Co Ltd
- Insiders 50.46%
- Institutions 3.24%
- Public & others 46.30%
- Shares outstanding 522M
- Free float 303M
Jiangxi Sanxin Medtec Co Ltd company profile
- Company name
- Jiangxi Sanxin Medtec Co Ltd
- Ticker
- 300453.SHE
- ISIN
- CNE100001ZJ1
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,297
- Fiscal year end
- December
- Address
- No. 999 Fushan Avenue, Nanchang, China, 330200
- Phone
- 86 79 1859 50320
- Website
- sanxin-med.com
About Jiangxi Sanxin Medtec Co Ltd
Jiangxi Sanxin Medtec Co.,Ltd. engages in the research and development, manufacture, sale, and service of medical devices. It offers infusion and cardiothoracic surgery products and blood purification products, such as central concentrate delivery systems, disposable biological protein glue dispensers, disposable blood dialyzers, hemodialysis filters, hemodialysis concentrates and powders, continuous blood purification pipelines and accessories, dialysis fluid filters, disposable dialysis indwelling needles, dialysis filtration machines, hemodialysis water production systems, centralized liquid supply systems, disposable hollow fiber dialyzers, hemodialysis extracorporeal circulation tubing, hemodialysis tubing, machine blood collection devices, blood purification and fluid replacement pipelines, and central venous catheter kits. It also provides prefilled catheter flushing devices, heparin caps, sterile needles, disposable filtration infusion sets, disposable light-shielded precision filtration infusion sets, blood transfusion devices, infusion disinfection connectors, Y-shaped indwelling needles, closed vein indwelling needles, pneumatic needle-free injectors, insulin syringes, injection needles, dispensing syringes, disposable sterile syringes, fixed-dose vaccine injectors, light-proof pressure extension tubes, positive pressure intravenous catheters, indwelling needles, and retractable self-destruct syringes. In addition, the company offers right heart suction heads, cardiopulmonary bypass connectors, blood clot filters, cold pump infusion devices, artificial heart-lung extracorporeal circulation tubing packages, and disposable blood storage and filtration devices. Further, it provides disposable balloon inflation pressure pumps, vascular sheath sets, and PTA high-pressure balloon dilation catheters, as well as medical needle-free injectors. Jiangxi Sanxin Medtec Co.,Ltd. was founded in 1997 and is headquartered in Nanchang, China.
Jiangxi Sanxin Medtec Co Ltd management
7- Mr. Zhiping MaoGM & Non-Independent Director · born 1974
- Mr. Ming LiuVP, Acting Financial Director, Board Secretary & Non-Independent Director · born 1989
- Ms. Ling PengVP & Non-independent Director · born 1982
- Ms. Ganying WangVice President · born 1980
- Ms. Lingli LengVice President · born 1983
- Mr. Bing Rong LiuVice President · born 1984
- Ms. Nan Mei ShuAccounting Officer